Literature DB >> 24011826

Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.

Carlos E Vigil1, Wei Tan, George Deeb, Sheila N Sait, Annemarie W Block, Petr Starostik, Elizabeth A Griffiths, James E Thompson, Jessica D Greene, Laurie A Ford, Eunice S Wang, Meir Wetzler.   

Abstract

We designed a phase II study evaluating the upfront combination of clofarabine and daunorubicin in acute myeloid leukemia (AML) patients≥60 years old. The median age of the 21 patients was 69 (range 60-85) years. Fourteen patients (67%) had unfavorable risk features. The principal toxicities were grade ≥3 infections and prolonged myelosuppression. Three (14%) deaths occurred from infectious complications. Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; Clinical trial; Clofarabine; Daunorubicin; Elderly

Mesh：

Substances：

Year:  2013        PMID： 24011826      PMCID： PMC3818466          DOI： 10.1016/j.leukres.2013.07.036

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  Drug resistance: still a daunting challenge to the successful treatment of AML.

Authors:  Brian C Shaffer; Jean-Pierre Gillet; Chirayu Patel; Maria R Baer; Susan E Bates; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-03-11       Impact factor: 18.500

Review 2.  Therapeutic advances in acute myeloid leukemia.

Authors:  Alan Burnett; Meir Wetzler; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

4.  Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Authors:  Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis J Giles; William Wierda; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

5.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Authors:  S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

6.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

Authors:  J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

Review 8.  Clofarabine: past, present, and future.

Authors:  Hagop M Kantarjian; Sima Jeha; Varsha Gandhi; Michael Wess; Stefan Faderl
Journal:  Leuk Lymphoma       Date:  2007-10

9.  Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.

Authors:  J A Montgomery; A T Shortnacy-Fowler; S D Clayton; J M Riordan; J A Secrist
Journal:  J Med Chem       Date:  1992-01-24       Impact factor: 7.446

10.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544
View more
  2 in total

1.  Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.

Authors:  Barbara Spitzer; Miguel-Angel Perales; Nancy A Kernan; Susan E Prockop; Emily C Zabor; Nicholas Webb; Hugo Castro-Malaspina; Esperanza B Papadopoulos; James W Young; Andromachi Scaradavou; Rachel Kobos; Sergio A Giralt; Richard J O'Reilly; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-13       Impact factor: 5.742

2.  Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.

Authors:  Harinder Gill; Rita Yim; Herbert H Pang; Paul Lee; Thomas S Y Chan; Yu-Yan Hwang; Garret M K Leung; Ho-Wan Ip; Rock Y Y Leung; Sze-Fai Yip; Bonnie Kho; Harold K K Lee; Vivien Mak; Chi-Chung Chan; June S M Lau; Chi-Kuen Lau; Shek-Yin Lin; Raymond S M Wong; Wa Li; Edmond S K Ma; Jun Li; Gianni Panagiotou; Joycelyn P Y Sim; Albert K W Lie; Yok-Lam Kwong
Journal:  Cancer Med       Date:  2020-03-18       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.